Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 26, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,753,646

« Back to Dashboard

Which drugs does patent 5,753,646 protect, and when does it expire?


Patent 5,753,646 protects APTIOM and is included in one NDA.

This patent has twenty-five patent family members in twenty countries.

Summary for Patent: 5,753,646

Title: Substituted dihydrodibenzo/b,f/azepines, method of their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
Abstract:New compounds of general formula I, including all possible stereoisomers, are described ##STR1## wherein: R is hydrogen, alkyl, aminoalkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, phenyl or substituted phenyl or pyridyl group. A process for their preparation consists of reaction of compound II ##STR2## with an acylating agent.
Inventor(s): Benes; Jan (Oporto, PT), Soares Da Silva; Patricio M. V. A. (Oporto, PT)
Assignee: Portela & Ca., S.A. (Oporto, PT)
Application Number:08/673,819
Patent Claim Types:
see list of patent claims
Compound; Process; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-001Nov 8, 2013RXYesNo5,753,646► SubscribeYY METHOD OF TREATING EPILEPSY
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-001Nov 8, 2013RXYesNo5,753,646► SubscribeYY APPROVED INDICATIONS:APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY.PATENT CLAIMS:IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-001Nov 8, 2013RXYesNo5,753,646► SubscribeYY MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-002Nov 8, 2013RXYesNo5,753,646► SubscribeYY METHOD OF TREATING EPILEPSY
Sunovion Pharms Inc
APTIOM
eslicarbazepine acetate
TABLET;ORAL022416-002Nov 8, 2013RXYesNo5,753,646► SubscribeYY APPROVED INDICATIONS:APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY.PATENT CLAIMS:IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,753,646

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Portugal101732Jun 30, 1995

International Patent Family for Patent: 5,753,646

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2180301► Subscribe
China1193965► Subscribe
China1070853► Subscribe
Germany69600985► Subscribe
Germany122009000049► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot